Targeting an anti CD11c antibody to CD11c positive cells led to the induction of strong CD4+ and CD8+ T cell responses, with the latter able to efficiently lyse ovalbumin expressing lymphoma cells (EL4) [227]. Here, ITGAX is linked to lymphoma.